ArticleHLA2026
HLA-F: A Non-Classical Gene With Growing Interest.
Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Last Licensed Non-Classical Peptide Presenter HLA-F: Its Occurrence, Immunoediting Significance, and Possible Therapeutic Implications in Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HLA-F is a non-classical HLA class I gene that belongs to the class Ib major histocompatibility complex (MHC) molecules. It is distinguished in the literature from its classical MHC class Ia counterparts by a minor frequency of polymorphisms. The exact function of HLA-F remains unknown, but recent publications emphasise the essential immunological role of this gene in infectious diseases, cancer research, organ transplantation and autoimmune diseases. The rapidly evolving sequencing techniques within the last years allow the accession of larger genomic regions at reasonable costs. In this regard we developed a long-range PCR assay, covering the entire HLA-F gene, including the flanking untranslated regions (UTRs). According to the positions of the 5' and 3' amplification primers, the PCR amplicon has a total length of 3.8 kb. After verification of our in-house developed LR-PCR with pre-typed cell-line derived DNA-samples from International HLA Reference Standards (IHWG), we analysed a randomly selected cohort of 763 DNA samples from the Stefan Morsch Stiftung stem cell donor registry on a MiSeq next generation sequencing (NGS) platform. This HLA-F genotyping project revealed so far unpublished data regarding the allele frequency distribution pattern as well as several new allelic variations, not listed yet in the IPD-IMGT/HLA Database. Prior to submission, all novel alleles were confirmed with Oxford Nanopore sequencing. Linkage disequilibrium between HLA-F and its neighbouring loci HLA-A and HLA-E was also assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.